Oppenheimer on Catalyst Pharmaceutical (CPRX): 'We believe that uncertainty around this topic had kept many on the sidelines and that today's update will facilitate investor interest'
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $29.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
